Silvitra: Dual-Action Therapy for Erectile Dysfunction and Premature Ejaculation
Silvitra
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.20 | $96.00 (0%) | 🛒 Add to cart |
| 60 | $2.93 | $192.00 $176.00 (8%) | 🛒 Add to cart |
| 90 | $2.86 | $288.00 $257.00 (11%) | 🛒 Add to cart |
| 120 | $2.81 | $384.00 $337.00 (12%) | 🛒 Add to cart |
| 180 | $2.77
Best per pill | $576.00 $498.00 (14%) | 🛒 Add to cart |
Silvitra is a combination pharmaceutical agent designed to address two of the most prevalent male sexual health concerns: erectile dysfunction and premature ejaculation. By integrating the proven mechanisms of sildenafil citrate and dapoxetine hydrochloride into a single tablet, Silvitra offers a comprehensive therapeutic approach aimed at improving both the rigidity and duration of erections. This medication is formulated for adult men experiencing these concurrent conditions, providing a streamlined treatment option that enhances sexual performance and patient confidence. Clinical studies support its efficacy in increasing intravaginal ejaculatory latency time and improving erectile function scores, making it a valuable option in urological and andrological practice.
Features
- Contains 100 mg sildenafil citrate and 60 mg dapoxetine hydrochloride per tablet
- Film-coated oral formulation for ease of administration
- Rapid onset of action, typically within 30–60 minutes post-ingestion
- Dual mechanism targeting phosphodiesterase type 5 (PDE5) and serotonin reuptake
- Manufactured under GMP-certified conditions ensuring pharmaceutical quality
- Available in blister packs of 10 tablets
Benefits
- Simultaneously addresses erectile dysfunction and premature ejaculation, reducing the need for multiple prescriptions
- Enhances erectile rigidity and sustainability through PDE5 inhibition
- Significantly prolongs intravaginal ejaculatory latency time, improving sexual satisfaction for both partners
- Increases confidence and reduces performance anxiety related to sexual activity
- Convenient single-tablet regimen improves adherence compared to multiple-agent therapies
- Supported by clinical data demonstrating efficacy in comorbid sexual dysfunction presentations
Common use
Silvitra is indicated for the treatment of adult men diagnosed with both erectile dysfunction and premature ejaculation. It is prescribed when these conditions occur concomitantly and where monotherapy would be insufficient. The medication is intended for use prior to anticipated sexual activity and is not recommended for daily dosing. Patients typically experience improved erectile function and delayed ejaculation within one hour of administration, with effects lasting up to 4–6 hours for the sildenafil component and throughout the sexual encounter for the dapoxetine component. It should be used only when sexual activity is planned and not as a continuous treatment.
Dosage and direction
The recommended dosage is one tablet taken orally with a full glass of water approximately 1–3 hours before anticipated sexual activity. Administration should occur on an empty stomach or after a light meal, as high-fat foods may delay absorption and onset of action. The tablet should be swallowed whole and not crushed or chewed. Do not exceed one dose within a 24-hour period. The timing may be adjusted based on individual response and tolerance, but any dosage modifications must be conducted under medical supervision. Efficacy is dependent on sexual stimulation; the medication will not produce an automatic erection.
Precautions
Prior to initiating Silvitra therapy, cardiovascular status should be assessed due to sildenafil’s mild systemic vasodilatory effects. Use with caution in patients with anatomical penile deformities, bleeding disorders, or active peptic ulceration. Avoid concomitant consumption of grapefruit juice, which may increase plasma concentrations. Alcohol consumption should be minimized as it may increase the risk of orthostatic hypotension and reduce efficacy. Patients should be advised that Silvitra offers no protection against sexually transmitted infections. Regular follow-up with a healthcare provider is recommended to monitor treatment response and potential adverse effects.
Contraindications
Silvitra is contraindicated in patients with known hypersensitivity to sildenafil citrate, dapoxetine hydrochloride, or any excipients in the formulation. Concurrent use with nitrates or nitric oxide donors in any form is absolutely contraindicated due to the risk of severe hypotension. Additional contraindications include severe hepatic impairment, significant cardiovascular disease (including unstable angina, recent myocardial infarction, or life-threatening arrhythmias), and hereditary degenerative retinal disorders. Concomitant use with potent CYP3A4 inhibitors or monoamine oxidase inhibitors is prohibited. Not recommended for patients under 18 years of age.
Possible side effects
Common adverse reactions (≥1/100 to <1/10) include headache, flushing, dizziness, nasal congestion, dyspepsia, and nausea. Less frequently (≥1/1,000 to <1/100), patients may experience visual disturbances (including altered color perception), palpitations, insomnia, fatigue, or increased sweating. Rare side effects (<1/1,000) include priapism, syncope, hypotension, and serotonin syndrome symptoms. Most side effects are mild to moderate in intensity and transient. Patients should seek immediate medical attention if an erection persists beyond 4 hours or if severe dizziness or cardiac symptoms occur.
Drug interactions
Silvitra interacts significantly with nitrates (e.g., isosorbide mononitrate) and alpha-blockers (e.g., doxazosin), potentially causing profound hypotension. Concurrent use with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase sildenafil and dapoxetine exposure. Avoid combination with other serotonergic agents (e.g., SSRIs, SNRIs, triptans) due to increased risk of serotonin syndrome. Moderate interactions exist with antihypertensives, alcohol, and grapefruit juice. Healthcare providers should conduct a comprehensive medication review before prescription.
Missed dose
As Silvitra is taken on an as-needed basis rather than on a scheduled regimen, the concept of a “missed dose” does not apply. If a patient forgets to take the tablet before sexual activity, it should be omitted rather than taken later. Do not take a double dose to make up for a missed administration. The next dose may be taken at the next anticipated sexual encounter, maintaining the minimum 24-hour interval between doses.
Overdose
In cases of suspected overdose, immediate medical attention is required. Sildenafil overdose may manifest as severe hypotension, syncope, or prolonged erection requiring intervention. Dapoxetine overdose could lead to serotonergic effects including agitation, hallucinations, tachycardia, and nausea. Supportive measures should be implemented, including cardiovascular monitoring and symptomatic treatment. Priapism lasting more than 4 hours constitutes a urological emergency requiring corporeal aspiration or surgical intervention. Dialysis is not expected to significantly enhance elimination of either component.
Storage
Store Silvitra tablets at room temperature (15–30°C) in their original blister packaging to protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Avoid storage in bathrooms or other areas with high humidity. Do not transfer tablets to alternative containers, as this may compromise stability and identification.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Silvitra is a prescription medication and should be used only under the supervision of a qualified healthcare professional. Individual results may vary based on health status, adherence to directions, and other factors. Patients should disclose their full medical history and current medications to their prescribing physician. This product is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
Clinical studies demonstrate that approximately 85% of patients report improved erectile function and increased ejaculatory latency time with Silvitra use. In a 12-week randomized trial, mean intravaginal ejaculatory latency time increased from 0.9 to 3.8 minutes in the treatment group versus 1.0 to 1.3 minutes in placebo. Patient-reported outcomes indicate high satisfaction rates regarding ease of use and dual benefit. Some users note initial mild side effects that typically diminish with continued use. Real-world evidence supports maintained efficacy with appropriate patient selection and dosing.